Global Arthritis Therapeutics Market
Global Arthritis Therapeutics Market

Arthritis Therapeutics Comprehensive Study by Route of Administration (Oral, Parenteral, Topical), Sales Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Drug Class (TNF Inhibitors, Interleukin Inhibitors, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Xanthine Oxidase Inhibitors, Others), Arthritis Type (Degenerative Arthritis (Osteoarthritis), Inflammatory Arthritis (Rheumatoid Arthritis), Infectious Arthritis, Metabolic Arthritis) Players and Region - Global Market Outlook to 2026

Arthritis Therapeutics Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Feb 2021 Edition 203 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
The study covers a detailed analysis segmented by key business segments i.e. and major geographies. Research Analyst at AMA predicts that United States and European Players will contribute to the maximum growth of Global Arthritis Therapeutics market throughout the predicted period.

What is Arthritis Therapeutics?
Arthritis Therapeutics is used to treat the inflammation of the joints. Arthritis can affect t can affect one joint or multiple joints. People of all ages, sex, and races can and do have arthritis, and it is the leading cause of disability in America. Joint pain, stiffness, and swelling are the most common symptoms of arthritis. As per sources, over 50 million adults and 300,000 children have some type of arthritis. It is most common among women and occurs more frequently in persons aging above 65 years. Globally, the annual incidence of rheumatoid arthritis is ~3 cases per 10,000 population and the prevalence rate is ~1%, increasing with age and peaking between the ages of 35 and 50 years. The rising cases of rheumatoid arthritis and osteoarthritis will drive the market growth throughout the forecast period.

The competition is expected to become even more intense in the years to come due to entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Arthritis Therapeutics market analysis report suggests strategies Players can follow and recommends key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, including:
  • Novartis AG (Switzerland)
  • Eli Lilly and Company (United States)
  • Amgen Inc. (United States)
  • Merck & Co., Inc. (United States)
  • Bristol-Myers Squibb Company (United States)
  • Pfizer Inc. (United States)
  • Johnson & Johnson (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Bayer AG (Germany)
  • Sanofi S.A. (France)


The global arthritis therapeutics market is highly competitive and consists of a limited number of vendors who compete with each other. The intense competition, changing consumer spending patterns, and demographic trends pose significant risk factors for manufacturer’s growth.

Market Trend
Self-Awareness And Pro-Activeness To Seek Treatment
Restraints
  • High Cost Of Arthritis Drugs

Opportunities
Increasing Obese Population Around The Globe and Rising Awareness About The Therapeutics In Emerging Economies

Key highlights of the Global Arthritis Therapeutics market Study:
• CAGR of the market during the forecast period 2020-2026
• Detailed information on factors that will accelerate the growth of the Arthritis Therapeutics market for the next five years.
• Forecast of the Global Arthritis Therapeutics market size and its contribution to the parent market by type, application and by country.
• Insights on upcoming trends and changes in consumer behaviour
• Uncovering market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Arthritis Therapeutics Players

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Arthritis Therapeutics market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Arthritis Therapeutics market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Arthritis Therapeutics Providers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists, Private Equity Firms, Government Regulatory and Research Organizations and End-User Industry.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Route of Administration
  • Oral
  • Parenteral
  • Topical

By Sales Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Drug Class
  • TNF Inhibitors
  • Interleukin Inhibitors
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Xanthine Oxidase Inhibitors
  • Others

By Arthritis Type
  • Degenerative Arthritis (Osteoarthritis)
  • Inflammatory Arthritis (Rheumatoid Arthritis)
  • Infectious Arthritis
  • Metabolic Arthritis

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing prevalence in geriatric population especially women
      • 3.2.2. Growing Use of Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    • 3.3. Market Challenges
      • 3.3.1. Growing Demand For Low-Priced Generics
    • 3.4. Market Trends
      • 3.4.1. Self-Awareness And Pro-Activeness To Seek Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Arthritis Therapeutics, by Route of Administration, Sales Channel, Drug Class, Arthritis Type and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Arthritis Therapeutics (Value)
      • 5.2.1. Global Arthritis Therapeutics by: Route of Administration (Value)
        • 5.2.1.1. Oral
        • 5.2.1.2. Parenteral
        • 5.2.1.3. Topical
      • 5.2.2. Global Arthritis Therapeutics by: Sales Channel (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Retail Pharmacies
        • 5.2.2.3. Online Pharmacies
      • 5.2.3. Global Arthritis Therapeutics by: Drug Class (Value)
        • 5.2.3.1. TNF Inhibitors
        • 5.2.3.2. Interleukin Inhibitors
        • 5.2.3.3. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
        • 5.2.3.4. Corticosteroids
        • 5.2.3.5. Xanthine Oxidase Inhibitors
        • 5.2.3.6. Others
      • 5.2.4. Global Arthritis Therapeutics by: Arthritis Type (Value)
        • 5.2.4.1. Degenerative Arthritis (Osteoarthritis)
        • 5.2.4.2. Inflammatory Arthritis (Rheumatoid Arthritis)
        • 5.2.4.3. Infectious Arthritis
        • 5.2.4.4. Metabolic Arthritis
      • 5.2.5. Global Arthritis Therapeutics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Arthritis Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Eli Lilly and Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Amgen Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck & Co., Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bristol-Myers Squibb Company (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Johnson & Johnson (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bayer AG (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sanofi S.A. (France)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Arthritis Therapeutics Sale, by Route of Administration, Sales Channel, Drug Class, Arthritis Type and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Arthritis Therapeutics (Value)
      • 7.2.1. Global Arthritis Therapeutics by: Route of Administration (Value)
        • 7.2.1.1. Oral
        • 7.2.1.2. Parenteral
        • 7.2.1.3. Topical
      • 7.2.2. Global Arthritis Therapeutics by: Sales Channel (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Retail Pharmacies
        • 7.2.2.3. Online Pharmacies
      • 7.2.3. Global Arthritis Therapeutics by: Drug Class (Value)
        • 7.2.3.1. TNF Inhibitors
        • 7.2.3.2. Interleukin Inhibitors
        • 7.2.3.3. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
        • 7.2.3.4. Corticosteroids
        • 7.2.3.5. Xanthine Oxidase Inhibitors
        • 7.2.3.6. Others
      • 7.2.4. Global Arthritis Therapeutics by: Arthritis Type (Value)
        • 7.2.4.1. Degenerative Arthritis (Osteoarthritis)
        • 7.2.4.2. Inflammatory Arthritis (Rheumatoid Arthritis)
        • 7.2.4.3. Infectious Arthritis
        • 7.2.4.4. Metabolic Arthritis
      • 7.2.5. Global Arthritis Therapeutics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Arthritis Therapeutics: by Route of Administration(USD Million)
  • Table 2. Arthritis Therapeutics Oral , by Region USD Million (2015-2020)
  • Table 3. Arthritis Therapeutics Parenteral , by Region USD Million (2015-2020)
  • Table 4. Arthritis Therapeutics Topical , by Region USD Million (2015-2020)
  • Table 5. Arthritis Therapeutics: by Sales Channel(USD Million)
  • Table 6. Arthritis Therapeutics Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 7. Arthritis Therapeutics Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 8. Arthritis Therapeutics Online Pharmacies , by Region USD Million (2015-2020)
  • Table 9. Arthritis Therapeutics: by Drug Class(USD Million)
  • Table 10. Arthritis Therapeutics TNF Inhibitors , by Region USD Million (2015-2020)
  • Table 11. Arthritis Therapeutics Interleukin Inhibitors , by Region USD Million (2015-2020)
  • Table 12. Arthritis Therapeutics Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) , by Region USD Million (2015-2020)
  • Table 13. Arthritis Therapeutics Corticosteroids , by Region USD Million (2015-2020)
  • Table 14. Arthritis Therapeutics Xanthine Oxidase Inhibitors , by Region USD Million (2015-2020)
  • Table 15. Arthritis Therapeutics Others , by Region USD Million (2015-2020)
  • Table 16. Arthritis Therapeutics: by Arthritis Type(USD Million)
  • Table 17. Arthritis Therapeutics Degenerative Arthritis (Osteoarthritis) , by Region USD Million (2015-2020)
  • Table 18. Arthritis Therapeutics Inflammatory Arthritis (Rheumatoid Arthritis) , by Region USD Million (2015-2020)
  • Table 19. Arthritis Therapeutics Infectious Arthritis , by Region USD Million (2015-2020)
  • Table 20. Arthritis Therapeutics Metabolic Arthritis , by Region USD Million (2015-2020)
  • Table 21. South America Arthritis Therapeutics, by Country USD Million (2015-2020)
  • Table 22. South America Arthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 23. South America Arthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 24. South America Arthritis Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 25. South America Arthritis Therapeutics, by Arthritis Type USD Million (2015-2020)
  • Table 26. Brazil Arthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 27. Brazil Arthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 28. Brazil Arthritis Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 29. Brazil Arthritis Therapeutics, by Arthritis Type USD Million (2015-2020)
  • Table 30. Argentina Arthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 31. Argentina Arthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 32. Argentina Arthritis Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 33. Argentina Arthritis Therapeutics, by Arthritis Type USD Million (2015-2020)
  • Table 34. Rest of South America Arthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 35. Rest of South America Arthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 36. Rest of South America Arthritis Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 37. Rest of South America Arthritis Therapeutics, by Arthritis Type USD Million (2015-2020)
  • Table 38. Asia Pacific Arthritis Therapeutics, by Country USD Million (2015-2020)
  • Table 39. Asia Pacific Arthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 40. Asia Pacific Arthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 41. Asia Pacific Arthritis Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 42. Asia Pacific Arthritis Therapeutics, by Arthritis Type USD Million (2015-2020)
  • Table 43. China Arthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 44. China Arthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 45. China Arthritis Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 46. China Arthritis Therapeutics, by Arthritis Type USD Million (2015-2020)
  • Table 47. Japan Arthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 48. Japan Arthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 49. Japan Arthritis Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 50. Japan Arthritis Therapeutics, by Arthritis Type USD Million (2015-2020)
  • Table 51. India Arthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 52. India Arthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 53. India Arthritis Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 54. India Arthritis Therapeutics, by Arthritis Type USD Million (2015-2020)
  • Table 55. South Korea Arthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 56. South Korea Arthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 57. South Korea Arthritis Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 58. South Korea Arthritis Therapeutics, by Arthritis Type USD Million (2015-2020)
  • Table 59. Taiwan Arthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 60. Taiwan Arthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 61. Taiwan Arthritis Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 62. Taiwan Arthritis Therapeutics, by Arthritis Type USD Million (2015-2020)
  • Table 63. Australia Arthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 64. Australia Arthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 65. Australia Arthritis Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 66. Australia Arthritis Therapeutics, by Arthritis Type USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Arthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Arthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Arthritis Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific Arthritis Therapeutics, by Arthritis Type USD Million (2015-2020)
  • Table 71. Europe Arthritis Therapeutics, by Country USD Million (2015-2020)
  • Table 72. Europe Arthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 73. Europe Arthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 74. Europe Arthritis Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 75. Europe Arthritis Therapeutics, by Arthritis Type USD Million (2015-2020)
  • Table 76. Germany Arthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 77. Germany Arthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 78. Germany Arthritis Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 79. Germany Arthritis Therapeutics, by Arthritis Type USD Million (2015-2020)
  • Table 80. France Arthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 81. France Arthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 82. France Arthritis Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 83. France Arthritis Therapeutics, by Arthritis Type USD Million (2015-2020)
  • Table 84. Italy Arthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 85. Italy Arthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 86. Italy Arthritis Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 87. Italy Arthritis Therapeutics, by Arthritis Type USD Million (2015-2020)
  • Table 88. United Kingdom Arthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 89. United Kingdom Arthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 90. United Kingdom Arthritis Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 91. United Kingdom Arthritis Therapeutics, by Arthritis Type USD Million (2015-2020)
  • Table 92. Netherlands Arthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 93. Netherlands Arthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 94. Netherlands Arthritis Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 95. Netherlands Arthritis Therapeutics, by Arthritis Type USD Million (2015-2020)
  • Table 96. Rest of Europe Arthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 97. Rest of Europe Arthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 98. Rest of Europe Arthritis Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 99. Rest of Europe Arthritis Therapeutics, by Arthritis Type USD Million (2015-2020)
  • Table 100. MEA Arthritis Therapeutics, by Country USD Million (2015-2020)
  • Table 101. MEA Arthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 102. MEA Arthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 103. MEA Arthritis Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 104. MEA Arthritis Therapeutics, by Arthritis Type USD Million (2015-2020)
  • Table 105. Middle East Arthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 106. Middle East Arthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 107. Middle East Arthritis Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 108. Middle East Arthritis Therapeutics, by Arthritis Type USD Million (2015-2020)
  • Table 109. Africa Arthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 110. Africa Arthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 111. Africa Arthritis Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 112. Africa Arthritis Therapeutics, by Arthritis Type USD Million (2015-2020)
  • Table 113. North America Arthritis Therapeutics, by Country USD Million (2015-2020)
  • Table 114. North America Arthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 115. North America Arthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 116. North America Arthritis Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 117. North America Arthritis Therapeutics, by Arthritis Type USD Million (2015-2020)
  • Table 118. United States Arthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 119. United States Arthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 120. United States Arthritis Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 121. United States Arthritis Therapeutics, by Arthritis Type USD Million (2015-2020)
  • Table 122. Canada Arthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 123. Canada Arthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 124. Canada Arthritis Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 125. Canada Arthritis Therapeutics, by Arthritis Type USD Million (2015-2020)
  • Table 126. Mexico Arthritis Therapeutics, by Route of Administration USD Million (2015-2020)
  • Table 127. Mexico Arthritis Therapeutics, by Sales Channel USD Million (2015-2020)
  • Table 128. Mexico Arthritis Therapeutics, by Drug Class USD Million (2015-2020)
  • Table 129. Mexico Arthritis Therapeutics, by Arthritis Type USD Million (2015-2020)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Arthritis Therapeutics: by Route of Administration(USD Million)
  • Table 141. Arthritis Therapeutics Oral , by Region USD Million (2021-2026)
  • Table 142. Arthritis Therapeutics Parenteral , by Region USD Million (2021-2026)
  • Table 143. Arthritis Therapeutics Topical , by Region USD Million (2021-2026)
  • Table 144. Arthritis Therapeutics: by Sales Channel(USD Million)
  • Table 145. Arthritis Therapeutics Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 146. Arthritis Therapeutics Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 147. Arthritis Therapeutics Online Pharmacies , by Region USD Million (2021-2026)
  • Table 148. Arthritis Therapeutics: by Drug Class(USD Million)
  • Table 149. Arthritis Therapeutics TNF Inhibitors , by Region USD Million (2021-2026)
  • Table 150. Arthritis Therapeutics Interleukin Inhibitors , by Region USD Million (2021-2026)
  • Table 151. Arthritis Therapeutics Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) , by Region USD Million (2021-2026)
  • Table 152. Arthritis Therapeutics Corticosteroids , by Region USD Million (2021-2026)
  • Table 153. Arthritis Therapeutics Xanthine Oxidase Inhibitors , by Region USD Million (2021-2026)
  • Table 154. Arthritis Therapeutics Others , by Region USD Million (2021-2026)
  • Table 155. Arthritis Therapeutics: by Arthritis Type(USD Million)
  • Table 156. Arthritis Therapeutics Degenerative Arthritis (Osteoarthritis) , by Region USD Million (2021-2026)
  • Table 157. Arthritis Therapeutics Inflammatory Arthritis (Rheumatoid Arthritis) , by Region USD Million (2021-2026)
  • Table 158. Arthritis Therapeutics Infectious Arthritis , by Region USD Million (2021-2026)
  • Table 159. Arthritis Therapeutics Metabolic Arthritis , by Region USD Million (2021-2026)
  • Table 160. South America Arthritis Therapeutics, by Country USD Million (2021-2026)
  • Table 161. South America Arthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 162. South America Arthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 163. South America Arthritis Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 164. South America Arthritis Therapeutics, by Arthritis Type USD Million (2021-2026)
  • Table 165. Brazil Arthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 166. Brazil Arthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 167. Brazil Arthritis Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 168. Brazil Arthritis Therapeutics, by Arthritis Type USD Million (2021-2026)
  • Table 169. Argentina Arthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 170. Argentina Arthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 171. Argentina Arthritis Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 172. Argentina Arthritis Therapeutics, by Arthritis Type USD Million (2021-2026)
  • Table 173. Rest of South America Arthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 174. Rest of South America Arthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 175. Rest of South America Arthritis Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 176. Rest of South America Arthritis Therapeutics, by Arthritis Type USD Million (2021-2026)
  • Table 177. Asia Pacific Arthritis Therapeutics, by Country USD Million (2021-2026)
  • Table 178. Asia Pacific Arthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 179. Asia Pacific Arthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 180. Asia Pacific Arthritis Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 181. Asia Pacific Arthritis Therapeutics, by Arthritis Type USD Million (2021-2026)
  • Table 182. China Arthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 183. China Arthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 184. China Arthritis Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 185. China Arthritis Therapeutics, by Arthritis Type USD Million (2021-2026)
  • Table 186. Japan Arthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 187. Japan Arthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 188. Japan Arthritis Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 189. Japan Arthritis Therapeutics, by Arthritis Type USD Million (2021-2026)
  • Table 190. India Arthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 191. India Arthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 192. India Arthritis Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 193. India Arthritis Therapeutics, by Arthritis Type USD Million (2021-2026)
  • Table 194. South Korea Arthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 195. South Korea Arthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 196. South Korea Arthritis Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 197. South Korea Arthritis Therapeutics, by Arthritis Type USD Million (2021-2026)
  • Table 198. Taiwan Arthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 199. Taiwan Arthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 200. Taiwan Arthritis Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 201. Taiwan Arthritis Therapeutics, by Arthritis Type USD Million (2021-2026)
  • Table 202. Australia Arthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 203. Australia Arthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 204. Australia Arthritis Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 205. Australia Arthritis Therapeutics, by Arthritis Type USD Million (2021-2026)
  • Table 206. Rest of Asia-Pacific Arthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 207. Rest of Asia-Pacific Arthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 208. Rest of Asia-Pacific Arthritis Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 209. Rest of Asia-Pacific Arthritis Therapeutics, by Arthritis Type USD Million (2021-2026)
  • Table 210. Europe Arthritis Therapeutics, by Country USD Million (2021-2026)
  • Table 211. Europe Arthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 212. Europe Arthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 213. Europe Arthritis Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 214. Europe Arthritis Therapeutics, by Arthritis Type USD Million (2021-2026)
  • Table 215. Germany Arthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 216. Germany Arthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 217. Germany Arthritis Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 218. Germany Arthritis Therapeutics, by Arthritis Type USD Million (2021-2026)
  • Table 219. France Arthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 220. France Arthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 221. France Arthritis Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 222. France Arthritis Therapeutics, by Arthritis Type USD Million (2021-2026)
  • Table 223. Italy Arthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 224. Italy Arthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 225. Italy Arthritis Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 226. Italy Arthritis Therapeutics, by Arthritis Type USD Million (2021-2026)
  • Table 227. United Kingdom Arthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 228. United Kingdom Arthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 229. United Kingdom Arthritis Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 230. United Kingdom Arthritis Therapeutics, by Arthritis Type USD Million (2021-2026)
  • Table 231. Netherlands Arthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 232. Netherlands Arthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 233. Netherlands Arthritis Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 234. Netherlands Arthritis Therapeutics, by Arthritis Type USD Million (2021-2026)
  • Table 235. Rest of Europe Arthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 236. Rest of Europe Arthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 237. Rest of Europe Arthritis Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 238. Rest of Europe Arthritis Therapeutics, by Arthritis Type USD Million (2021-2026)
  • Table 239. MEA Arthritis Therapeutics, by Country USD Million (2021-2026)
  • Table 240. MEA Arthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 241. MEA Arthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 242. MEA Arthritis Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 243. MEA Arthritis Therapeutics, by Arthritis Type USD Million (2021-2026)
  • Table 244. Middle East Arthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 245. Middle East Arthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 246. Middle East Arthritis Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 247. Middle East Arthritis Therapeutics, by Arthritis Type USD Million (2021-2026)
  • Table 248. Africa Arthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 249. Africa Arthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 250. Africa Arthritis Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 251. Africa Arthritis Therapeutics, by Arthritis Type USD Million (2021-2026)
  • Table 252. North America Arthritis Therapeutics, by Country USD Million (2021-2026)
  • Table 253. North America Arthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 254. North America Arthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 255. North America Arthritis Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 256. North America Arthritis Therapeutics, by Arthritis Type USD Million (2021-2026)
  • Table 257. United States Arthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 258. United States Arthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 259. United States Arthritis Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 260. United States Arthritis Therapeutics, by Arthritis Type USD Million (2021-2026)
  • Table 261. Canada Arthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 262. Canada Arthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 263. Canada Arthritis Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 264. Canada Arthritis Therapeutics, by Arthritis Type USD Million (2021-2026)
  • Table 265. Mexico Arthritis Therapeutics, by Route of Administration USD Million (2021-2026)
  • Table 266. Mexico Arthritis Therapeutics, by Sales Channel USD Million (2021-2026)
  • Table 267. Mexico Arthritis Therapeutics, by Drug Class USD Million (2021-2026)
  • Table 268. Mexico Arthritis Therapeutics, by Arthritis Type USD Million (2021-2026)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Arthritis Therapeutics: by Route of Administration USD Million (2015-2020)
  • Figure 5. Global Arthritis Therapeutics: by Sales Channel USD Million (2015-2020)
  • Figure 6. Global Arthritis Therapeutics: by Drug Class USD Million (2015-2020)
  • Figure 7. Global Arthritis Therapeutics: by Arthritis Type USD Million (2015-2020)
  • Figure 8. South America Arthritis Therapeutics Share (%), by Country
  • Figure 9. Asia Pacific Arthritis Therapeutics Share (%), by Country
  • Figure 10. Europe Arthritis Therapeutics Share (%), by Country
  • Figure 11. MEA Arthritis Therapeutics Share (%), by Country
  • Figure 12. North America Arthritis Therapeutics Share (%), by Country
  • Figure 13. Global Arthritis Therapeutics share by Players 2020 (%)
  • Figure 14. Global Arthritis Therapeutics share by Players (Top 3) 2020(%)
  • Figure 15. Global Arthritis Therapeutics share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 19. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 20. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 21. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Amgen Inc. (United States) Revenue: by Geography 2020
  • Figure 23. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 25. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 26. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2020
  • Figure 27. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 29. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 30. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 31. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2020
  • Figure 33. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 35. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 36. Sanofi S.A. (France) Revenue: by Geography 2020
  • Figure 37. Global Arthritis Therapeutics: by Route of Administration USD Million (2021-2026)
  • Figure 38. Global Arthritis Therapeutics: by Sales Channel USD Million (2021-2026)
  • Figure 39. Global Arthritis Therapeutics: by Drug Class USD Million (2021-2026)
  • Figure 40. Global Arthritis Therapeutics: by Arthritis Type USD Million (2021-2026)
  • Figure 41. South America Arthritis Therapeutics Share (%), by Country
  • Figure 42. Asia Pacific Arthritis Therapeutics Share (%), by Country
  • Figure 43. Europe Arthritis Therapeutics Share (%), by Country
  • Figure 44. MEA Arthritis Therapeutics Share (%), by Country
  • Figure 45. North America Arthritis Therapeutics Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Novartis AG (Switzerland)
  • Eli Lilly and Company (United States)
  • Amgen Inc. (United States)
  • Merck & Co., Inc. (United States)
  • Bristol-Myers Squibb Company (United States)
  • Pfizer Inc. (United States)
  • Johnson & Johnson (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Bayer AG (Germany)
  • Sanofi S.A. (France)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation